TIGECYCLINE PRODUCTS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Tigecycline is an antibiotic available under brand name Tygacil which is used to treat serious bacterial infections such as urinary tract infections, acne, gonorrhea, and chlamydia. Tigecycline is used as an alternative agent for the treatment of resistant gram positive and gram negative infection, especially in patients with a history of penicillin allergy or antimicrobial related toxicities. Moreover, tigecycline binds to bacterial ribosomes and prevents bacterial ribosomes from producing cell protein needed for bacterial growth and multiplication but does not kill bacteria. Tigecycline is administrated through intravenous infusion over 30 to 60 minutes and initial dose of tigecycline for bacterial infection treatment is 100 mg followed by 50 mg every 12 hour. Moreover, for complicated skin infection, recommended duration of treatment is 14 to 15 days and 7 to 14 days for treatment of community-acquired bacterial pneumonia.

Global Tigecycline  Products Market: Drivers

The increasing prevalence of gonorrhea in the U.S. is driving demand for tigecycline products in the market. For instance, according to the Centers for Disease Control and Prevention’s 2017 report, in the U.S, around 555,608 cases of gonorrhea were reported. Therefore, pharmaceutical companies are focusing on launching products for treatment of bacterial infections due to increasing prevalence. For instance, in 2017, Sandoz Inc. launched AP-rated generic version of Tygacil (Tigecycline) injection at a cheaper price compared to branded products in order to increase affordability of the drug. These factors are expected to drive growth of global tigecycline products market.

Global Tigecycline Products Market: COVID-19 Impact Analysis

The COVID-19 pandemic has affected several markets across the globe. Pharmaceutical companies are facing difficulties such as regulatory revisions, changes in demand, delay in generic medicine approvals, disruption in supply chain, and product exportation restriction due to lockdown policies implemented by governments. These factors are negatively affecting the growth of the global tigecycline products market.

Global Tigecycline  Products Market: Restraints

Tigecycline antibiotic is characterized by side effects such as lower back or side pain, painful or difficult urination, problems with vision or hearing, cough or hoarseness, fever or chills, and headache. Moreover,the use of  tigecycline is restricted due to increase in mortality in hospital-acquired or ventilator-associated pneumonia. Moreover, patients prefer oral tablets (amoxicillin) to injection (tigecycline) for treatment of bacterial infection, due to the cost effectiveness of oral amoxicillin. Cost of 500 mg amoxicillin oral tablet is US$ 23.99, while cost of the tigecycline injection is US$ 79.22. These factors are expected to restrain growth of the global tigecycline products market.

Global Tigecycline  Products Market: Regional Analysis

On the basis of region, the global tigecycline products market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. In North America, the demand for use of tigecycline is increasing due to high prevalence of chlamydia trachomtis. For instance, according to the Centers for Disease Control and Prevention, in 2016, 1,598,354 cases of chlamydia trachomatis infection were reported in the U.S., and 497.3 cases per 100,000 were reported in 2015. Therefore, pharmaceutical companies are focusing on product launches for the treatment of bacterial infectious disease. For instance, in 2016, Fresenius Kabi announced the launch of Tigecycline injection, a generic version of Pfizer’s tygacil with single dose vial in the U.S.

In Europe, there is major burden of chlamydia and gonorrhea due to increasing prevalence. For instance, according to the National Health Service’s 2018 report, in England, over 44,500 people were diagnosed with gonorrhea in men and women of age under 25 in 2017. Therefore, pharmaceutical companies are focusing on launching product for treatment of bacterial infectious diseases. For instance, in February 2020, European Medicines Agency approved marketing authorization of tigecycline injection by Accord Healthcare for treatment of bacterial skin diseases. These factors are expected to drive growth of the global tigecycline products market during the forecast period.

Global Tigecycline  Products Market: Key Players

Key players operating in the global tigecycline products market are Amneal Pharmaceuticals, Inc., Novartis International AG, Xellia pharmaceuticals ApS, Accord Healthcare Inc., Apotex, Inc., Aurobindo Pharma Limited, Fresenius Kabi USA LLC, Pfizer Inc., Abbott Laboratories, and AstraZeneca plc.

Market Taxonomy:

On the basis of application, the global tigecycline  products market is segmented into:

• Urinary Tract Infections (UTI)
• Skin and Soft Tissue Infections
• Complicated Intra-Abdominal Infections
• Community-acquired Bacterial Pneumonia
• Gonorrhea
• Chlamydia
• Others

On the basis of distribution channel, the global tigecycline  products market is segmented into:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

On the basis of region, the global tigecycline  products market is segmented into:

• North America
• Latin America
• Europe
• Middle East
• Asia Pacific
• Africa